Clinical Peptidomics: Advances in Instrumentation, Analyses, and Applications  

作　　者：Lin Li Jing Wu Christopher JLyon Li Jiang Tony Y.Hu 

机构地区：[1]Center for Cellular and Molecular Diagnostics,Department of Biochemistry and Molecular Biology,School of Medicine,Tulane University,New Orleans,LA,USA [2]Department of Laboratory Medicine and Sichuan Provincial Key Laboratory for Human Disease Gene Study,Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital,Chengdu,China [3]Department of Clinical Laboratory,Third Central Hospital of Tianjin,Tianjin Institute of Hepatobiliary Disease,Tianjin Key Laboratory of Artificial Cell,Artificial Cell Engineering Technology Research Center of Public Health Ministry,Tianjin,China [4]Department of Biomedical Engineering,School of Science and Engineering,Tulane University,New Orleans,LA,USA

出　　处：《Biomedical Engineering Frontiers》2023年第1期116-132,共17页生物医学工程前沿（英文）

基　　金：The work was primarily supported by research funding provided by the National Cancer Institute(U01CA252965);Eunice Kennedy Shriver National Institute of Child Health and Human Development(R01HD090927 and R01HD103511);National Institute of Allergy and Infectious Diseases(R01AI144168);U.S.Department of Defense(W8IXWH1910926);National Institute of Neurological Disorders and Stroke(R21NS130542).

摘　　要：Extensive effort has been devoted to the discovery,development,and validation of biomarkers for early disease diagnosis and prognosis as well as rapid evaluation of the response to therapeutic interventions.Genomic and transcriptomic profiling are well-established means to identify disease-associated biomarkers.However,analysis of disease-associated peptidomes can also identify novel peptide biomarkers or signatures that provide sensitive and specific diagnostic and prognostic information for specific malignant,chronic,and infectious diseases.Growing evidence also suggests that peptidomic changes in liquid biopsies may more effectively detect changes in disease pathophysiology than other molecular methods.Knowledge gained from peptide-based diagnostic,therapeutic,and imaging approaches has led to promising new theranostic applications that can increase their bioavailability in target tissues at reduced doses to decrease side effects and improve treatment responses.However,despite major advances,multiple factors can still affect the utility of peptidomic data.This review summarizes several remaining challenges that affect peptide biomarker discovery and their use as diagnostics,with a focus on technological advances that can improve the detection,identification,and monitoring of peptide biomarkers for personalized medicine.

关 键 词：doses gained devoted 

分 类 号：R318[医药卫生—生物医学工程]